A curative treatment for at least three of the top five deadliest cancers is approved by the FDA before Octobe

Question

Six frontier AI models put this at 7% by 22 Sept 2036. Full reasoning from every model.

WillHappen.ai · Accepted Answer

7% — the median of 6 frontier models, resolving by 2036-09-22.

Answer

Gemini (Google): 4% — Clinical validation of curative efficacy requires 5- to 10-year survival data that trials entering Phase 1 today cannot yield by 2036. Top killers like pancreatic, lung, and colorectal cancer exhibit high heterogeneity and stromal barriers resistant to single therapies. The FDA rarely approves explicitly curative label claims without massive long-term disease-free survival data from Phase 3 trials. Ten years is barely enough time for one novel biologic to clear discovery through approval, let alone three distinct tumor regimes.

Answer

Claude (Anthropic): 4% — Requires FDA approval of curative (not just extended-survival) treatments for 3+ of lung, colorectal, pancreatic, liver, breast cancers by 2036. No oncology treatment today is labeled 'curative' by FDA for any of these cancers at advanced stages; approvals use survival/response endpoints, not cure claims. CAR-T and mRNA vaccine successes so far are concentrated in blood cancers and melanoma, not the deadliest solid tumors like pancreatic or lung cancer. A decade is enough for major incremental gains but historically insufficient for regulatory 'curative' labeling across three distinct high-mortality cancer types…

Answer

GPT (OpenAI): 9% — This hinges on whether durable, broadly reproducible cures emerge in pancreatic, lung, colorectal, liver, or breast cancer—not just long remissions. FDA approvals require randomized evidence of major survival benefit; “curative” outcomes must persist across heterogeneous, often metastatic disease by 2036. In the last decade, targeted drugs and cell therapies transformed subsets but FDA labels rarely establish cures for common lethal solid tumors. Odds rise sharply if trials show long-term treatment-free survival in resectable pancreatic or metastatic lung cancer by 2030, enabling confirmatory studies.

Answer

Grok (xAI): 12% — FDA must green-light truly curative (not palliative) agents for 3 of 5 high-mortality solid tumors by 2036. No metastatic lung, pancreatic or colorectal cancer has been cured by any FDA-approved drug in the last 15 years despite checkpoint inhibitors and KRAS G12C agents. mRNA vaccines and next-gen CAR-T still lack completed Phase 3 OS data; even accelerated paths need 4–6 years of follow-up before a 2034–35 filing. A single pancreatic or NSCLC complete-response rate >30 % in a registrational trial would raise odds, but historical complete-response rates remain <5 %.

Answer

DeepSeek (DeepSeek): 12% — This turns on whether any single modality can convert a metastatic top-five killer into a durable cure, not just a life-extending therapy. The top five killers (lung, colorectal, pancreatic, breast, prostate) are mostly caught late; FDA approves drugs for survival benefit, not 'cure,' so the bar is efficacy… Pancreatic and lung have seen real progress (KRAS G12D inhibitors, osimertinib adjuvant), but five-year metastatic survival remains under 10% for most, and approval… The development that would flip this: a CAR-T or mRNA neoantigen vaccine showing durable complete responses in a phase III solid-tumor trial by ~2030, which no modality…

Answer

Qwen (Alibaba): 3% — No curative therapy has ever been FDA-approved for a solid tumor, and three such approvals in ten years is unprecedented. The top five deadliest cancers (lung, colorectal, pancreatic, breast, prostate) are overwhelmingly solid tumors; CAR-T and mRNA vaccines have not yet produced a single… FDA approval of a 'curative' treatment requires demonstrating durable complete remission in pivotal trials—typically 5-8 years from Phase I to approval, leaving almost… Even the most optimistic pipeline (e.g., mRNA neoantigen vaccines for melanoma/pancreatic cancer, CAR-T for pancreatic) has at most one or two candidates in early-phase…

A curative treatment for at least three of the top five deadliest cancers is approved by the FDA before October 2036.

What each one said

A curative treatment for at least three of the top five deadliest cancers is approved by the FDA before October 2036.

A universal cure or vaccine effectively eliminating cancer mortality across most major types is approved by regulatory agencies before 2040.

The World Health Organization explicitly characterizes a Hantavirus outbreak as a pandemic in 2026.

An AI system is granted full regulatory approval to independently diagnose and prescribe treatment without doctor oversight by 2032.

A universal or broadly curative therapy for most major cancer types is approved before 2035.